Explore the growing importance of routine germline sequencing in cancer diagnostics and precision oncology.

This article from Eurofins Viracor BioPharma examines how paired germline testing can help distinguish tumor-specific mutations from alterations associated with clonal hematopoiesis (CH)—a critical consideration for accurate diagnosis and treatment decision-making in patients with advanced solid tumors. The findings highlight the potential consequences of mutation misclassification and the need for comprehensive genomic profiling in modern cancer care.

Key topics include:

• The role of routine germline sequencing in precision oncology
• The challenges of differentiating clonal hematopoiesis-related mutations from tumor-derived alterations
• How paired germline and tumor testing supports more accurate molecular interpretation
• The implications of mutation misclassification on treatment decisions and patient outcomes
• Emerging opportunities to integrate comprehensive genomic profiling into personalized cancer care strategies

As precision oncology continues to evolve, incorporating routine germline sequencing into cancer diagnostics may help improve molecular characterization, support informed treatment decisions, and advance more personalized approaches to patient care.